samedan logo
 
 
 
spacer
home > ebr > summer 2019 > the future of r&d in alzheimer’s disease
PUBLICATIONS
European Biopharmaceutical Review

The Future of R&D in Alzheimer’s Disease

Earlier this year, the failures of two high-profile, antiamyloid- beta (Aβ) monoclonal antibodies (mAbs) in late-stage clinical trials have sharpened the focus on two key issues that currently dominate the quest to establish effective treatments for Alzheimer’s disease (AD): the need to develop drugs that are highly selective for the Aß conformation known to be the pathogenic cause of AD (ie, soluble neurotoxic Aβ oligomers [AβOs]) and the need to employ emerging AD biomarkers to dramatically transform clinical trial design and enable cost-effective, earlier go/nogo decisions on investigational therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Dr Neil Cashman is a Physician and Scientist recognised worldwide as one of the leading researchers pioneering the emerging fields of prion biology and protein misfolding disease, in particular, Alzheimer’s disease and amyotrophic lateral sclerosis. His research has attracted more than US $50 million in funding, including grants from the National Institutes of Health. Neil is a past recipient of the Jonas Salk Prize for biomedical research and current Fellow of the Canadian Academy of Health Sciences.

Dr James W Kupiec has led both early- and late-stage development teams working on investigational therapies for a wide variety of neurologic and psychiatric disorders for the past 25 years. He began his career practising internal medicine, serving on faculty at both the University of Rochester School of Medicine, US, and the SUNY Upstate Medical University, US, before shifting to commercial posts. James most recently served as Vice President, Global Clinical Leader for Parkinson’s Disease, and Clinical Head of the Neuroscience Research Unit in Cambride for Pfizer.
spacer
Dr Neil Cashman
spacer
spacer
spacer
Dr James W Kupiec
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement